Specify a stock or a cryptocurrency in the search bar to get a summary
Inozyme Pharma Inc
INZYInozyme Pharma, Inc., a clinical-stage rare disease biopharmaceutical company, focuses on developing novel therapeutics for the treatment of vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant, genetically engineered, and fusion protein for the treatment of ENPP1 and ABCC6 deficiencies, as well as patients with end-stage kidney disease receiving hemodialysis. It has a license agreement with Yale University for specified therapeutic and prophylactic products. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts. Address: 321 Summer Street, Boston, MA, United States, 02210
Analytics
WallStreet Target Price
19 USDP/E ratio
–Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures INZY
Dividend Analytics INZY
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History INZY
Stock Valuation INZY
Financials INZY
Results | 2019 | Dynamics |